Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 14;18(3):613-617.
doi: 10.1016/j.stemcr.2023.01.013. Epub 2023 Feb 23.

Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan

Tsunakuni Ikka  1 , Misao Fujita  2 , Taichi Hatta  3 , Tetsu Isobe  4 , Kenji Konomi  5 , Tatsuo Onishi  6 , Shoji Sanada  7 , Yuichiro Sato  8 , Shimon Tashiro  9 , Morikuni Tobita  10
Affiliations
Review

Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan

Tsunakuni Ikka et al. Stem Cell Reports. .

Erratum in

Abstract

We outlined five studies regarding the quality of the review by committees based on the Act on the Safety of Regenerative Medicine. The findings raise serious concerns about the independence, integrity, and quality of reviews of therapeutic plans by these committees with inappropriately close relationships to medical institutions and companies.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests We conducted the studies commissioned by the MHLW. This paper is based on a part of the report published as outcomes of the commissioned projects.

Figures

None
Graphical abstract
Figure 1
Figure 1
Inappropriate three-way relationships for the independence and integrity of CSCRM reviews
See this image and copyright information in PMC

References

    1. Abolarinwa B.A., Shaw M.K., Lee C.H. Perspectives on challenges to cell therapy development in Taiwan: strengthening evidential standards and ways forward. Front. Bioeng. Biotechnol. 2021;9:789043. doi: 10.3389/fbioe.2021.789043. - DOI - PMC - PubMed
    1. Fu W., Smith C., Turner L., Fojtik J., Pacyna J.E., Master Z. Characteristics and scope of training of clinicians participating in the US direct-to-consumer marketplace for unproven stem cell interventions. JAMA. 2019;321:2463–2464. doi: 10.1001/jama.2019.5837. - DOI - PMC - PubMed
    1. Fujita M., Hatta T., Ide K. Current status of cell-based interventions in Japan. Cell Stem Cell. 2022;29:1294–1297. doi: 10.1016/j.stem.2022.08.003. - DOI - PubMed
    1. Health Science Council . Report “Building a framework for safety assurance and promotion of RM”. 2013. Expert committee on safety assurance and promotion of RM.https://www.mhlw.go.jp/stf/shingi/2r9852000002zggt-att/2r9852000002zgkl.pdf
    1. Health Science Council, Regenerative Medicine Evaluation Committee. The interim report on the review of the law for enforcement of act on the safety of regenerative medicine 5 years after its enforcement (2019). https://www.mhlw.go.jp/content/000581069.pdf.

Publication types